Revagenix
2 known investors
Find your way into Revagenix
Sign up to see every warm intro you have to Revagenix
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Revagenix team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Revagenix is a precision-therapeutics company that develops drugs for serious chronic diseases, starting from the underlying biology and unmet clinical needs. Its lead program, Rev-56, is an inhaled therapy with a novel mechanism of action designed for non-CF bronchiectasis (NCFB).
Founders & leadership

Investors · 2
How we know: Tenmile's portfolio page · the company's own site · funding news · prnewswire.com · Not right? Tell us
How we know: the company's own site · funding news · prnewswire.com · Not right? Tell us
Funding
SEC filings, press & company announcements- Undisclosed amountSeries BJan 2024 · 2 sources
Tenmile (lead), Novo Holdings
Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does Revagenix do?
- Revagenix is a precision-therapeutics company that develops drugs for serious chronic diseases, starting from the underlying biology and unmet clinical needs. Its lead program, Rev-56, is an inhaled therapy with a novel mechanism of action designed for non-CF bronchiectasis (NCFB).
- Who founded Revagenix?
- Revagenix was founded by Ryan Cirz, Andrew McCandlish.
- Who are Revagenix's investors?
- Revagenix's investors include Tenmile, Novo Holdings.



